Ventripoint Aims for EU Approval with AI Heart Tech
Company Announcements

Ventripoint Aims for EU Approval with AI Heart Tech

Story Highlights

VentriPoint Diagnostics (TSE:VPT) has released an update.

Ventripoint Diagnostics has announced the submission of its AI-enhanced heart-scanning technology, VMS+4.0, for EU MDR certification, indicating a pivotal advancement in its regulatory journey. The VMS+4.0 system streamlines clinical workflow with minimal manual input and is already in use across various countries, awaiting further approval in the EU.

For further insights into TSE:VPT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskVentripoint Diagnostics Reveals New Convertible Debenture Offering
TipRanks Canadian Auto-Generated NewsdeskVentripoint Earns EU CE Mark for AI Heart Tech
TipRanks Canadian Auto-Generated NewsdeskVentripoint Diagnostics Closes First Private Placement Tranche
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App